Indurthi also predicts the industry will see developments in gene-editing technologies, largely supported by growing partnerships: “Despite the many difficulties associated with gene editing technology, the industry has seen impressive developments in research and the recent approval of the first-ever gene editing medicine is something we are poised to build on.
Indurthi also predicts the industry will see developments in gene-editing technologies, largely supported by growing partnerships: “Despite the many difficulties associated with gene editing technology, the industry has seen impressive developments in research and the recent approval of the first-ever gene editing medicine is something we are poised to build on. These developments are also being spurred by increasingly significant partnerships, like the recently announced Danaher Corporation-Innovative Genomics Institute Beacon for CRISPR Cures, which seeks to build and take to clinic gene editing medicines to treat rare and other diseases.”